Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

Overview

Journal Clin Transl Gastroenterol

Specialty Gastroenterology

Date 2016 Jan 8

PMID 26741065

Citations 275

Authors

Giulia Roda

Bindia Jharap

Narula Neeraj

Jean-Frederic Colombel

Affiliations

Soon will be listed here.

Abstract

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of inflammatory bowel diseases patients leading to an improvement of patient's quality of life with the reduction of number of surgeries and hospitalizations. Despite these advances, many patients do not respond to the induction therapy (primary non-response-PNR) or lose response during the treatment (secondary loss of response-LOR). In this paper we will provide an overview of the definition, epidemiology and risk factors for PNR and LOR, as well as discuss the therapeutic options for managing LOR.

Citing Articles

Rapid Resolution of Perianal Crohn's Disease with Upadacitinib.

Brennan K, Beniwal-Patel P ACG Case Rep J. 2025; 12(2):e01623.

PMID: 39963477 PMC: 11832199. DOI: 10.14309/crj.0000000000001623.

Exploring the connection between erythrocyte membrane fatty acid composition and oxidative stress in patients undergoing the Crohn's disease Therapeutic Diet Intervention (CD-TDI).

Haskey N, Letef C, Sousa J, Yousuf M, Taylor L, McKay D Therap Adv Gastroenterol. 2025; 18:17562848251314827.

PMID: 39963251 PMC: 11831646. DOI: 10.1177/17562848251314827.

Therapeutic drug monitoring and immunogenetic factors associated with the use of adalimumab in Crohn's disease patients.

Genaro L, Carron J, de Castro M, Franceschini A, Lourenco G, Cruz C Int J Immunopathol Pharmacol. 2025; 39:3946320251319379.

PMID: 39959979 PMC: 11831650. DOI: 10.1177/03946320251319379.

Insights into adverse events and safety profile of upadacitinib in the management of inflammatory bowel diseases - A meta-analysis of randomized controlled trials.

Falcon B, de Mello Guimaraes T, Halpern G, Gomes C, de Mello Guimaraes T Indian J Gastroenterol. 2025; .

PMID: 39921836 DOI: 10.1007/s12664-024-01720-0.

Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn's Disease in the United States and Europe.

Kershaw J, Sanon M, Kachroo S, Barlow S, Naessens D, Willey C Crohns Colitis 360. 2025; 7(1):otae074.

PMID: 39834357 PMC: 11744185. DOI: 10.1093/crocol/otae074.

References

Allez M, Karmiris K, Louis E, Van Assche G, Ben-Horin S, Klein A . Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis. 2010; 4(4):355-66. DOI: 10.1016/j.crohns.2010.04.004. View

Hanauer S, Feagan B, Lichtenstein G, Mayer L, Schreiber S, Colombel J . Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359(9317):1541-9. DOI: 10.1016/S0140-6736(02)08512-4. View

Ben-Horin S, Yavzori M, Katz L, Kopylov U, Picard O, Fudim E . The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut. 2010; 60(1):41-8. DOI: 10.1136/gut.2009.201533. View

Farrell R, Alsahli M, Jeen Y, Falchuk K, Peppercorn M, Michetti P . Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology. 2003; 124(4):917-24. DOI: 10.1053/gast.2003.50145. View

Mazor Y, Almog R, Kopylov U, Ben Hur D, Blatt A, Dahan A . Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther. 2014; 40(6):620-8. DOI: 10.1111/apt.12869. View

Sprakes M, Ford A, Warren L, Greer D, Hamlin J . Efficacy, tolerability, and predictors of response to infliximab therapy for Crohn's disease: a large single centre experience. J Crohns Colitis. 2012; 6(2):143-53. DOI: 10.1016/j.crohns.2011.07.011. View

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A . Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2014; 13(3):522-530.e2. DOI: 10.1016/j.cgh.2014.07.029. View

Colombel J, Feagan B, Sandborn W, Van Assche G, Robinson A . Therapeutic drug monitoring of biologics for inflammatory bowel disease. Inflamm Bowel Dis. 2011; 18(2):349-58. DOI: 10.1002/ibd.21831. View

Roblin X, Marotte H, Rinaudo M, Del Tedesco E, Moreau A, Phelip J . Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2013; 12(1):80-84.e2. DOI: 10.1016/j.cgh.2013.07.010. View

10.

Baert F, Noman M, Vermeire S, Van Assche G, D Haens G, Carbonez A . Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348(7):601-8. DOI: 10.1056/NEJMoa020888. View

11.

Hanauer S, Sandborn W, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130(2):323-33. DOI: 10.1053/j.gastro.2005.11.030. View

12.

Vande Casteele N, Gils A . Preemptive Dose Optimization Using Therapeutic Drug Monitoring for Biologic Therapy of Crohn's Disease: Avoiding Failure While Lowering Costs?. Dig Dis Sci. 2015; 60(9):2571-3. DOI: 10.1007/s10620-015-3673-1. View

13.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

14.

Sandborn W, Hanauer S, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56(9):1232-9. PMC: 2701613. DOI: 10.1136/gut.2006.106781. View

15.

Ben-Horin S, Chowers Y . Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011; 33(9):987-95. DOI: 10.1111/j.1365-2036.2011.04612.x. View

16.

Ainsworth M, Bendtzen K, Brynskov J . Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol. 2007; 103(4):944-8. DOI: 10.1111/j.1572-0241.2007.01638.x. View

17.

Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P . Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013; 108(6):962-71. DOI: 10.1038/ajg.2013.12. View

18.

Alten R, Van den Bosch F . Dose optimization of infliximab in patients with rheumatoid arthritis. Int J Rheum Dis. 2014; 17(1):5-18. DOI: 10.1111/1756-185X.12202. View

19.

Billioud V, Sandborn W, Peyrin-Biroulet L . Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review. Am J Gastroenterol. 2011; 106(4):674-84. DOI: 10.1038/ajg.2011.60. View

20.

Jones G, Kennedy N, Lees C, Arnott I, Satsangi J . Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn's disease maintenance--progress and prospects. Aliment Pharmacol Ther. 2014; 39(11):1253-65. DOI: 10.1111/apt.12743. View